Responses

PDF
Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Re: Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis
    • Carl C. Awh, -
    • Other Contributors:
      • Brent Zanke, ArcticDX

    We read with interest the article by Seddon, Silver, and Rosner1, in which the authors studied progression from intermediate AMD to either geographic atrophy or choroidal neovascularization as a function of genetic risk and AREDS treatment assignment. This study of 4124 eyes by leaders in AMD genetic epidemiology is by far the largest series to analyze and validate a gene/treatment interaction. The authors show that CFH an...

    Show More
    Conflict of Interest:
    None declared.